BEROCCA PN
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Jul 1947
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BEROCCA PN is an injectable small-molecule therapeutic sponsored by Roche, approved in 1947. The product indications and mechanism of action are not publicly detailed in available data. It represents a legacy injectable formulation in Roche's portfolio with approaching loss of exclusivity.
LOE Approaching
As an aging small-molecule injectable approaching loss of exclusivity, BEROCCA PN likely operates within a stable, mature team focused on lifecycle extension and generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Only 2 linked positions suggest limited hiring momentum. Roles span early-career scientist and intern levels, indicating this product supports junior development talent rather than senior brand leadership. Career progression may be constrained by the product's mature lifecycle stage.
Scientist IDevelopment Center Protein Development Intern
Worked on BEROCCA PN at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.